Cell therapy's poster child: Chimeric antigen receptor T cell therapy / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 2339-2349, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-781634
ABSTRACT
Chimeric antigen receptor T (CAR-T) cell therapy, which adoptively transfers engineered T cells expressing synthetic receptors to target specific antigens, has achieved great clinical success in treating hematological malignancies. Though FDA has approved two CAR-T products, CAR-T therapy can cause some side effects, such as cytokine release syndrome (CRS), neurotoxicity and B cell aplasia. Meanwhile, lacking tumor specific antigen and the suppressive tumor environment limit the efficacy of CAR-T therapy in solid tumor. This review focuses on the structural components, clinical applications and synthetic biology approaches on CAR-T cell design, and summarizes the challenges and perspectives of CAR-T therapy as a revolutionary cancer immunotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Receptors, Antigen, T-Cell
/
T-Lymphocytes
/
Immunotherapy, Adoptive
/
Cell- and Tissue-Based Therapy
/
Receptors, Chimeric Antigen
/
Immunotherapy
Limits:
Child
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Biotechnology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS